Emmecell secures strategic financing to enhance clinical programs and expand its magnetic cell delivery platform, supported by Bausch + Lomb.
Round Type
Funding Round
Menlo ParkBiotechnologyHealth CareTherapeuticsInvestors
Description
Emmecell, a clinical-stage biotechnology company, closes a strategic financing round to advance its clinical programs. This funding will enhance operational capabilities and develop its proprietary magnetic cell delivery technologies. With the support of existing investors and Bausch + Lomb, the company aims to address significant clinical needs in ophthalmic diseases. Emmecell's innovative approach targets treatment options for patients affected by corneal endothelial disease.
Quick answer
Emmecell raised an undisclosed amount in a Funding Round round, dated June 16, 2026. Investors: Bausch + Lomb. Emmecell is based in Menlo Park, California, United States.
- How much did Emmecell raise?
- Emmecell raised an undisclosed amount in a Funding Round round on June 16, 2026.
- Who invested in Emmecell?
- Bausch + Lomb is named as investors in this round.
- What does Emmecell do?
- Emmecell is a clinical-stage biotechnology company developing magnetic cell delivery technologies to treat corneal disease, geographic atrophy, and other ophthalmic conditions.
- Where is Emmecell based and how big is it?
- Emmecell is based in Menlo Park, California, United States.
- Who are the decision-makers at Emmecell?
- Fundz holds 2 contacts at Emmecell, including the Chief Operating Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Emmecell that raised within 45 days of this round, from Fundz verified event records.
- Ratio Therapeutics raised $70M (Series C) on July 31, 2026.
- Hyku Biosciences raised $8.6M on July 30, 2026.
- HCW Biologics raised $1.5M (Post-IPO Equity) on July 29, 2026.
- Adjuvia Therapeutics raised $8M (Seed) on July 29, 2026.
- CORE Biomedicine raised $21M (Series A) on July 28, 2026.
- Torrey Pines Medicine raised an undisclosed amount (Angel) on July 28, 2026.
Who to call at Emmecell, and when
A new round usually means Emmecell is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Emmecell raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Emmecell, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Emmecell. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Emmecell raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Emmecell raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.